Takara Bio revises forecasts downwards, executive pay adjusted

Takara Bio Inc. announced a correction to its November 11, 2025, disclosure regarding revisions to its full-year consolidated financial results forecast and dividend forecast for the fiscal year ending March 31, 2026. The primary change highlighted was an adjustment to the "Net income per share" figure in the "Revised forecasts (B)" row, which was corrected from △78.06 yen to △74.74 yen.

The revised consolidated forecasts for the fiscal year ending March 31, 2026, show a notable decline compared to previously announced figures. Net sales are now projected at 42,100 million yen, down from 52,500 million yen, representing a 19.8% decrease. Operating profit is expected to be a loss of 4,000 million yen, a substantial reduction from the previous forecast of 2,500 million yen profit.

Similarly, ordinary profit is now projected as a loss of 4,400 million yen, revised from a 2,500 million yen profit. Net income attributable to owners of the parent is forecast to be a loss of 9,000 million yen, a significant downturn from the previously anticipated 1,300 million yen profit, leading to the corrected △74.74 yen loss per share.